{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007922","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.413324+00:00","generated_at":"2026-06-08T05:05:01.204856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform","bullets":["Net loss of $1.1M for Q3 2023; cash at $9.8M.","R&D expenses rose 155.9% to $1.0M on DNase platform preclinical work.","Royalty income from Takeda sublicense up 47.5% to $0.6M.","Advancing DNase platform toward first-in-human study for pancreatic carcinoma.","G&A expenses down 14.6% to $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007922","json":"https://secwatch.observer/filing/0001683168-23-007922.json","markdown":"https://secwatch.observer/filing/0001683168-23-007922.md","text":"https://secwatch.observer/filing/0001683168-23-007922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/0001683168-23-007922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:05:01.204856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e24e0d111ae33a5b496b36229820720f1cc096b8","claim":"Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2023.","evidence_excerpt":"On November 10, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/0001683168-23-007922-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}